- Home
- VIVS vs NXTS Comparison
VIVS vs NXTS Comparison
Compare VIVS & NXTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VIVS | NXTS |
|---|---|---|
| Founded | 2007 | 2009 |
| Country | United States | Israel |
| Employees | 9 | 9 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Agricultural Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9M | 3.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | VIVS | NXTS |
|---|---|---|
| Price | $1.31 | $5.84 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 25.6K | ★ 39.0K |
| Earning Date | 06-04-2026 | 05-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $42.38 | N/A |
| Revenue Next Year | $15.42 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.22 | $0.55 |
| 52 Week High | $5.30 | $6.25 |
Technical Indicators
Market Signals| Indicator | VIVS | NXTS |
|---|---|---|
| Relative Strength Index (RSI) | 37.72 | 65.71 |
| Support Level | $1.24 | $3.97 |
| Resistance Level | $1.88 | $6.23 |
| Average True Range (ATR) | 0.07 | 0.71 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 37.84 | 65.20 |
Price Performance
Historical ComparisonAbout VIVS VivoSim Labs Inc.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
About NXTS Nexentis Technologies Inc. Common Stock
Nexentis Technologies Inc, is engaged in redefining mitochondrial drug discovery with help of its wholly owned biotechnology subsidiary, MitoCareX Bio focused on drug discovery company dedicated to developing first-in-class therapeutics for inflammatory metabolic diseases and cancer by targeting specific metabolic pathways. The company is also focused on sustainable operations in various industries such as solar projects, and oncology biotechnology.